A Study of the Effects of Pregabalin on Colon Function

Overview

About this study

The purpose of this study is to evaluate the effects of pregabalin, a drug approved for anticonvulsive therapy and for neuropathic pain, on colonic and sensory functions in healthy individuals.

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Healthy males or females

Exclusion Criteria

  • Abdominal surgery other than appendectomy, laparoscopic cholecystectomy, cesarean section, vaginal or laparoscopic hysterectomy or tubal ligation
  • A history of chronic gastrointestinal or systemic illnesses that could affect gastrointestinal motility
  • Any history of hypertension
  • Use of medications that may alter gastrointestinal motility or interact with the study medications
  • Use of any of the study medications within the past 30 days
  • Pregnancy
  • Chronic renal insufficiency (serum creatinine >1.5 mg/dL)
  • Psychiatric or psychologic dysfunction

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Michael Camilleri, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available
.
CLS-20312635

Mayo Clinic Footer